A Phase 2/3 Multicenter, Dose-response Study to Assess Efficacy and Safety of ZS (Sodium Zirconium Cyclosilicate), in Japanese Patients With Hyperkalemia

Trial Profile

A Phase 2/3 Multicenter, Dose-response Study to Assess Efficacy and Safety of ZS (Sodium Zirconium Cyclosilicate), in Japanese Patients With Hyperkalemia

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Zirconium silicate (Primary)
  • Indications Hyperkalaemia
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Jun 2017 Planned End Date changed from 16 Oct 2017 to 16 Mar 2018.
    • 19 Jun 2017 Planned primary completion date changed from 16 Oct 2017 to 16 Mar 2018.
    • 16 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top